Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: Possible implications for hepatotoxicity

Pharmacotherapy

Volumn 30, Issue 1, 2010, Pages 17-24

  McRae, MaryPeace ^a   Rezk, Naser L ^a   Bridges, Arlene S ^a   Corbett, Amanda H ^a   Tien, Hsiao Chuan ^a   Brouwer, Kim L R ^a   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bile acids; Cholic acid; Hepatotoxicity; HIV; Human immunodeficiency virus; Protease inhibitor

Indexed keywords

AMPRENAVIR; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; LITHOCHOLIC ACID; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; TAUROCHOLIC ACID; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILE ACID BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALE; RETROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY;

ADULT; BILE ACIDS AND SALTS; CHENODEOXYCHOLIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG-INDUCED LIVER INJURY; EARLY DIAGNOSIS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LITHOCHOLIC ACID; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TANDEM MASS SPECTROMETRY; TAUROCHOLIC ACID; TIME FACTORS;

EID: 75149117397     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.1.17     Document Type: Article

References (30)

1. Bremmelgaard A, Sjovall J. Hydroxylation of cholic, chenodeoxycholic, and deoxycholic acids in patients with intrahepatic cholestasis. J Lipid Res 1980;21:1072-81.
2. Bloomer JR, Allen RM, Klatskin G. Serum bile acids in primary biliary cirrhosis. Arch Intern Med 1976;136:57-61.
3. Magyar I, Loi HG, Feher T. Plasma bile acid levels and liver disease. Acta Med Acad Sci Hung 1981;38:109-15.
4. Azer SA, Coverdale SA, Byth K, Farrell GC, Stacey NH. Sequential changes in serum levels of individual bile acids in patients with chronic cholestatic liver disease. J Gastroenterol Hepatol 1996;11:208-15.
5. Okuda H, Obata H, Nakanishi T, Hisamitsu T, Matsubara K, Watanabe H. Quantification of individual serum bile acids in patients with liver diseases using high-performance liquid chromatography. Hepatogastroenterology 1984;31:168-71.
6. Morita T, Matsuyama Y, Fujimoto T, Higuchi M, Tsujii T, Matsuoka Y. Clinical significance of serum bile acid measurement in liver diseases. Gastroenterol Jpn 1978;13:491-502.
7. Laatikainen T. Postprandial serum bile acids in cholestasis of pregnancy. Ann Clin Res 1978;10:307-12.
8. Laatikainen T, Ikonen E. Serum bile acids in cholestasis of pregnancy. Obstet Gynecol 1977;50:313-18.
9. Galeazzi R, Lorenzini I, Orlandi F. Rifampicin-induced elevation of serum bile acids in man. Dig Dis Sci 1980;25:108-12.
10. Neghab M, Qu S, Bai CL, Caples J, Stacey NH. Raised concentration of serum bile acids following occupational exposure to halogenated solvents, 1,1,2-trichloro-1,2,2-trifluoroethane and trichloroethylene. Int Arch Occup Environ Health 1997;70:187-94.
11. Shima T, Tada H, Morimoto M, et al. Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J Gastroenterol Hepatol 2000;15:294-9.
12. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-31.
13. Tripodi V, Nunez M, Carducci C, Mamianetti A, Agost Carreno C. Total serum bile acids in renal transplanted patients receiving cyclosporine A. Clin Nephrol 2002;58:350-5.
14. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba AD. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 2004;36:921-8.
15. Ahlberg J, Angelin B, Bjorkhem I, Einarsson K. Individual bile acids in portal venous and systemic blood serum of fasting man. Gastroenterology 1977;73:1377-82.
16. Tagliacozzi D, Mozzi AF, Casetta B, et al. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med 2003;41:1633-41.
17. Costarelli V, Sanders TA. Plasma deoxycholic acid concentration is elevated in postmenopausal women with newly diagnosed breast cancer. Eur J Clin Nutr 2002;56:925-7.
18. Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003;42:81-92.
19. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005;6:114-21.
20. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001;98:12671-6.
21. Abbott Laboratories. Norvir (ritonavir) product Information. Abbott Park, IL; 2005.
22. Bristol-Myers Squibb. Reyataz (atazanavir) product Information. Princeton, NJ; 2006.
23. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004;38(suppl 2):S90-7.
24. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
25. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001;59:627-35.
26. Kemp DC, Zamek-Gliszczynski MJ, Brouwer KL. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 2005;83:207-14.
27. Kostrubsky SE, Strom SC, Kalgutkar AS, et al. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 2006;90:451-9.
28. McRae MP, Lowe CM, Tian X, et al. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 2006;318:1068-75.
29. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159:2647-58.
30. Lu Y, Heydel JM, Li X, Bratton S, Lindblom T, Radominska-Pandya A. Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element. Drug Metab Dispos 2005;33:937-46.